Haleon has launched as an independent company on 18 July 2022 – 100% focused on consumer health, completing its demerger from GSK. The newly listed business is driven by its purpose to deliver better everyday health with humanity.
About Haleon
Haleon (LSE: HLN) is a global leader in consumer health, with brands trusted by millions of consumers globally. Haleon employs over 22,000 people across 170 markets, who are united by Haleon’s purpose – to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories – Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands – such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, Parodontax and Centrum – are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com
About Haleon Indonesia
Haleon (LSE: HLN) is a global leader in consumer health, with brands trusted by millions of consumers globally. Haleon Indonesia (PT Sterling Products Indonesia and PT GSK Consumer Healthcare Indonesia) employs over 400 people whose purpose is to deliver better everyday health with humanity. With market leading positions in oral care and wellness, Haleon works closely with pharmacists, physicians, and retailers to increase awareness of everyday healthcare issues and concerns and emphasise the importance of self-care. Haleon’s Pulogadung site in Jakarta also supplies countries in the Southeast Asia region with high quality and innovative consumer healthcare products, such as Panadol and Actifed.
For more information, please visit www.haleon.com
